QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
48.26 USD +2.68% Intraday chart for QuidelOrtho Corporation +1.77% -34.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
QuidelOrtho Receives Canada's Approval for Triage PLGF Test to Detect Pregnancy Complications MT
Transcript : QuidelOrtho Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 04:00 PM
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
QuidelOrtho Shares Decline Following UBS Downgrade MT
UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70 MT
Sector Update: Health Care Stocks Mixed in Late Afternoon MT
Sector Update: Health Care MT
QuidelOrtho Terminates CEO Douglas Bryant, Postpones Investor Day MT
QuidelOrtho Corporation Announces CEO Changes CI
QuidelOrtho Corporation Announces Changes in Executive Leadership, Effective from February 21, 2024 CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Top Midday Decliners MT
QuidelOrtho Shares Slump After Analysts Downgrade Stock Following Lower Q4 Results MT
William Blair Downgrades QuidelOrtho to Market Perform From Outperform MT
Citigroup Adjusts Price Target on QuidelOrtho to $50 From $72, Maintains Neutral Rating MT
Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158 MT
Raymond James Downgrades QuidelOrtho to Outperform From Strong Buy, Cuts Price Target to $76 From $100 MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
JPMorgan Downgrades QuidelOrtho to Underweight From Neutral, Adjusts Price Target to $37 From $66 MT
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Traders Recover From Inflation Figures Shock MT
RBC Adjusts PT on QuidelOrtho to $81 From $130, Notes Worse-Than-Anticipated COVID Headwinds; Outperform Kept on 'Compelling' Risk/Reward MT
Top Premarket Decliners MT
Chart QuidelOrtho Corporation
More charts
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its capabilities include immunoassay and molecular testing, clinical chemistry and transfusion medicine. The Company's business units include Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology, Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform, VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells, InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel, QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage, Virena, and Vitros.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
48.26 USD
Average target price
56 USD
Spread / Average Target
+16.04%
Consensus
  1. Stock
  2. Equities
  3. Stock QuidelOrtho Corporation - Nasdaq
  4. News QuidelOrtho Corporation
  5. Quidel : to Market COVID-19 Home Test Kits at CVS Pharmacies, Online Next Week